History
From Vision to Innovation: The Birth of GVS
GVS was founded in 1979 by Grazia Valentini, supported by her father Renato, a pioneer in injection mould design. Initially focused on medical filters for blood treatment, the company quickly expanded, opening two new plants in Italy and securing its first patent in 1986 for an infusion device with air intakes.
Pioneering Filtration Solutions for a Changing World
In 1993, GVS acquired Valplast srl, marking its entry into the Automotive sector and creating the Energy & Mobility division. The company began its global expansion with offices in Belgrade (1993), Buenos Aires (1997), and a plant in Brazil (1998). During this period, GVS earned ISO9001 certification and other quality and environmental accreditations.
Global Expansion and Leadership Transition
The 2000s saw new plants in Southern Italy and offices in China, the USA, and Mexico. In 2003, Massimo Scagliarini became CEO, guiding GVS through acquisitions in China, Spain, Italy, and the UK, even during the global financial crisis. Patents continued to strengthen its position in healthcare and automotive filtration.
Strategic Growth and New Divisions
GVS reorganized and expanded into Japan, Korea, and Russia, completing six acquisitions. The Health & Safety division was launched in 2015, reinforced by acquisitions in Brazil and Italy. Patents during this era included innovations in ventilation and building filtration.
Breaking Borders, Building Leadership
The Group acquired companies in Sweden, the USA, and Puerto Rico, becoming a global leader in white blood cell filters. In 2020, GVS listed on the Italian Stock Exchange, confirming its robust growth strategy.
Expanding Horizons: A New Era for GVS
Between 2021 and 2025, GVS embarked on a transformative journey, redefining its role on the world stage. With a bold expansion into Asia, marked by new offices in Thailand and a state-of-the-art production hub in Suzhou, China, alongside the opening of a new manufacturing plant in the United Kingdom, GVS significantly strengthened its global presence. Strategic acquisitions, including RPB, Shanghai Transfusion Technology, Haemotronic, and Haemonetics’ Whole Blood business, fueled the creation of the Transfusion Medicine division. These milestones are more than growth, they represent GVS’s commitment to innovation, leadership, and a vision to advance healthcare filtration worldwide.